Recent Updates
Recently added Catalysts
GOSS Positive Sentiment

PROSERA, a Phase 3 Study of the Efficacy and Safety of Seralutinib in Adults with Pulmonary Arterial Hypertension

Thursday, August 15, 2024 BiopharmaWatch Research 2 min read
Add on Google
Key Takeaway: The PROSERA study is a Phase 3 clinical trial evaluating the efficacy and safety of Seralutinib in adults diagnosed with Pulmonary Arterial Hypertension (PAH). This trial represents a significant step in the development of new treatment options for this serious condition. The study aims to provide critical data that could influence future therapeutic strategies.
Price reaction · baseline $0.827 (2024-08-14 close) · hit pre-market · 2 other GOSS headline(s) in the window, move may be shared
day 0 close
-0.3%

Market Sentiment Analysis

POSITIVE FACTORS

  • Phase 3 study indicates advanced clinical development stage.
  • Focus on efficacy and safety for a serious condition, PAH.
  • Potential for significant impact on treatment options for patients.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+53%
120-day peak, hindsight
Typical move
5.9%
average across 2 past catalysts
Cash runway
~4 mo
High dilution risk
Lead asset
GB001
Phase 2 · Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)

Full Press Release Details

PROSERA, a Phase 3 Study of the Efficacy and Safety of Seralutinib in Adults with Pulmonary Arterial Hypertension
• About Overview Team Management Board of Directors Collaboration Contact Locations Contact Form Sponsorship Disclosure
• Seralutinib About Seralutinib PAH PH-ILD Posters & Presentations
• Patients Overview Expanded Access
• Investors Overview News Events & Presentations Events Presentations Filings Governance Overview Committee Composition Management Board of Directors Stock Stock Quote & Chart Historical Price Lookup Investment Calculator Analyst Coverage Info FAQs Contact IR Email Alerts
• Careers & Culture Who We Are Open Positions
• Overview
• Team
• Management
• Board of Directors
• Collaboration
• Contact
• Locations
• Contact Form
• Sponsorship Disclosure
• About Seralutinib
• PAH
• PH-ILD
• Posters & Presentations
• Overview
• Expanded Access
• Overview
• News
• Events & Presentations Events Presentations
• Filings
• Governance Overview Committee Composition Management Board of Directors
• Stock Stock Quote & Chart Historical Price Lookup Investment Calculator Analyst Coverage
• Info FAQs Contact IR Email Alerts
• Events
• Presentations
• Overview
• Committee Composition
• Management
• Board of Directors
• Stock Quote & Chart
• Historical Price Lookup
• Investment Calculator
• Analyst Coverage
• FAQs
• Contact IR
• Email Alerts
• Who We Are
• Open Positions

Frequently Asked Questions

What is the PROSERA study about?

The PROSERA study is a Phase 3 clinical trial assessing the efficacy and safety of Seralutinib in adults with Pulmonary Arterial Hypertension.

What condition does Seralutinib target?

Seralutinib is being evaluated for its effectiveness in treating Pulmonary Arterial Hypertension (PAH).

What phase is the Seralutinib study currently in?

The study of Seralutinib is currently in Phase 3 of clinical trials.

Why is the PROSERA study important?

The PROSERA study is crucial as it aims to provide data that could enhance treatment options for patients with PAH.

ShareAdd on Google
Tags: GOSS Viatris Investor Conferences Healthcare Seralutinib Pulmonary Arterial Hypertension clinical trial efficacy
Last updated: Aug 15, 2024

Biotech snapshot

Cash runway
$57M liquidity · $13M/mo burn
~4 mo
High dilution risk
Lead asset
GB001Phase 2
Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) →

Catalyst track record

+53%
best trade around GOSS's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for GOSS.

See every catalyst's timing & PoA →